Prostate Cancer Daily

May 25, 2026

Videos

Peer-to-Peer Clinical Conversations

MEVPRO-1 and MEVPRO-2 Trials of EZH2 Inhibitor Mevrometostat in mCRPC - Neeraj Agarwal

Neeraj Agarwal

Neeraj Agarwal presents the MEVPRO-1 and MEVPRO-2 trial designs, grounding them in phase 2 data showing that mevrometostat, an EZH2 inhibitor, added to enzalutamide improved rPFS from 6 months to 14.

View

CAN-2409 with Valacyclovir and Radiation for Localized Prostate Cancer - Mark Garzotto

M Garzotto

Mark Garzotto presents an extended data cut from the CAN-2409 trial.

View

Beyond the Abstracts

Pushing the Boundaries of SBRT in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study - Beyond the Abstract

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Conference Coverage

AUA 2026: Real-world Characteristics, Treatment Utilization, and Outcomes Among Patients with Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Treated in Community Urology Centers in the US: A PRECISION Data Platform Study

AUA 2026: Redefining EMBARK-like Patients in the PSMA Era: Impact of PSMA-PET Restaging on Disease Classification and Management

AUA 2026: Real-World Outcomes of Triplet Intensification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer in Japanese Patients from the Prospective YUSHIMA Registry: Propensity-Weighted and Bayesian RMST Analysis

APCCC 2026: Which Patients with Synchronous, Metastatic Hormone-Sensitive Prostate Cancer Benefit from Prostate Radiotherapy? STOPCAP Meta-Analysis of Individual Participant Data

APCCC 2026: The Importance of Baseline Testosterone and Testosterone Recovery in High Risk and Locally Advanced Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Radioligand Therapy Hormone Combinations and the ENZA-p Trial.

Elective Nodal Radiotherapy in Localized Prostate Cancer: A Meta-Analysis.

Partial gland ablation for radio-recurrent prostate cancer: Short-term oncological and functional outcomes.

Frailty and Quality of Life in Low-Income, Uninsured Men with Prostate Cancer.

Racial and ethnic differences in prostate cancer screening outcomes in the United States: A secondary analysis of the prostate, lung, colorectal, and ovarian cancer trial.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login